Cellvizio® is the real-time in vivo cellular imaging platform that significantly improves the classification of indeterminate cysts quickly and with more certainty.
Up to 30% of cases remain indeterminate after endoscopic ultrasonography (EUS)1 and over 50% of cysts are inconclusive after fine-needle aspiration (FNA).2
As a result, 60% of patients with benign pancreatic cysts undergo unnecessary surgery due to uncertain diagnoses.3 Moreover, standard of care accuracy for the diagnosis of mucinous pancreatic cystic lesions (PCLs) is 71%.4
Cellvizio improves diagnostic accuracy, enabling you to confidently manage patients and reduce surgical intervention.
Cellvizio® Clinical Value
Cellvizio® improves characterization of indeterminate cysts5, which allows physicians to reduce surgical intervention by 23%.6 As a result, 35% of patients with benign serous cystadenoma (SCA) are prevented from further surveillance.5
Needle-based Confocal Laser Endomicroscopy (nCLE) with Cellvizio® allows you to see the cyst wall at the microscopic level, in real time, for the first time through a high-speed flexible microscope threaded inside a 19-gauge needle during EUS-FNA procedures. This improves accuracy for the diagnosis of mucinous PCLs to 97% with nCLE alone.4
See one patient case of nCLE in Pancreatic Cyst Assessment with Dr. Bertrand Napoléon, a gastroenterologist and interventional endoscopist.
“My approach to evaluating pancreatic cystic lesions is revolutionized, creating a major change in patient management."
Dr. C. J. DiMaio, Mount Sinai Hospital
Characterization of Cyst
using Cellvizio® AQ-FlexTM 19 Miniprobe
Non-Mucinous - Serous cystadenoma
Criteria: superficial vascular networking
Criteria: papillary projection
Criteria: epithelial border
With Cellvizio, diagnosis is more conclusive.5
The outcomes are positive results that help to completely change patient management by characterizing indeterminate cysts.5
Therapeutic decisions are modified by 28%, which eliminates follow ups for some patients.5
Surveillance of benign SCA is eliminated in 35% of cases.5
This allows for a 23% reduction in unnecessary surgeries and a significant economic benefit of a 13% reduction in cost.6
1. Rodríguez-D’Jesús A, et al. Impact of endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration on the management of pancreatic cystic lesions. Eur J Gastroenterol Hepatol, 2016.
2. Thornton GD. et al. Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis. Pancreatology, 2013.
3. Jais B. et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut 2015
4. Krishna SG, et al. Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy Increases Accuracy of Differentiation of Pancreatic Cystic Lesions. Clinical Gastroenterology and Hepatology, 2019.
5. Palazzo et al. Impact of needle-based confocal laser endomicroscopy on the therapeutic management of single pancreatic cystic lesions, Surgical Endoscopy, 2019.
6. Le Pen C et al. A health economic evaluation of needle-based Confocal Laser Endomicroscopy for the diagnosis of pancreatic cysts. Endoscopy International Open (2017).